In this month’s featured publication, Dr. Ligon and colleagues analyzed 134 diffuse intrinsic pontine glioma (DIPG) samples for their genetic make-up.  They determined that the DIPG tumors are associated with a particular mutation H3K27M, which is the initial driver of tumor formation, and that this mutation is maintained throughout the course of disease.  These findings confirm the use of needle biopsies for DIPG as the best method of sampling the tumor to find the driver, and that therapy should be focused on early systemic tumor control.